Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, successfully passed resolutions at its 2024 Annual General Meeting. The company is advancing its lead asset, ATH434, in Phase 2 clinical trials targeting Multiple System Atrophy, while also expanding its drug discovery platform. Based in Melbourne and San Francisco, Alterity aims to revolutionize treatments for Parkinsonian disorders.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.